Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients

Haque, Waqar; Voong, Khinh Ranh; Shihadeh, Ferial; Arzu, Isidora; Pinnix, Chelsea C.; Mazloom, Ali; Medeiros, L. Jeffrey; Romaguera, Jorge; Rodriguez, Alma; Wang, Michael; Allen, Pamela K.; Dabaja, Bouthaina S.

doi:10.1016/j.clml.2014.07.003

Cited by 24 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, a current recommendation includes shortened conventional chemotherapy induction followed by consolidating radiation for MCL patients carrying high tumor burden (> 5 cm are presented below) and/or having poor prognostic factors (blastoid features, high Ki67 indices (> 20-40%), high β 2 microglobulin (> 3 mg/l), and central nervous system involvement [6, 90]. In such cases, systemic therapy as indicated for advanced stages (see below) would be appropriate; however, radiotherapy alone has been reported to be equally effective even in MCL patients with relapse or with bulky tumor and/or extra-nodal presentation [91, 92]. Based on clinical trials on indolent and untreated MCL (Table 2), intense chemo-immunotherapy in young patients appeared to induce complete remission but was associated with higher side effects [93].…”

Section: Therapeutic Approaches For MCLmentioning

confidence: 99%

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

et al. 2016

View full text Add to dashboard Cite

Despite advances in the development of clinical agents for treating Mantle Cell Lymphoma (MCL), treatment of MCL remains a challenge due to complexity and frequent relapse associated with MCL. The incorporation of conventional and novel diagnostic approaches such as genomic sequencing have helped improve understanding of the pathogenesis of MCL, and have led to development of specific agents targeting signaling pathways that have recently been shown to be involved in MCL. In this review, we first provide a general overview of MCL and then discuss about the role of biomarkers in the pathogenesis, diagnosis, prognosis, and treatment for MCL. We attempt to discuss major biomarkers for MCL and highlight published and ongoing clinical trials in an effort to evaluate the dominant signaling pathways as drugable targets for treating MCL so as to determine the potential combination of drugs for both untreated and relapse/refractory cases. Our analysis indicates that incorporation of biomarkers is crucial for patient stratification and improve diagnosis and predictability of disease outcome thus help us in designing future precision therapies. The evidence indicates that a combination of conventional chemotherapeutic agents and novel drugs designed to target specific dysregulated signaling pathways can provide the effective therapeutic options for both untreated and relapse/refractory MCL.

show abstract

Section: Therapeutic Approaches For MCLmentioning

confidence: 99%

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In series that have integrated RT, the overall response rates were as great as 100%, with a complete response achieved in 64% to 69% of patients (20,21). Such data suggest that MCL is indeed radiosensitive.…”

Section: Discussionmentioning

confidence: 81%

Management Trends and Outcomes for Stage I to II Mantle Cell Lymphoma Using the National Cancer Data Base: Ascertaining the Ideal Treatment Paradigm

Gill

Vargo

Balasubramani

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…Ultra‐low‐dose radiation has become standard in treating many primary skin lymphomas. Recent reports have shown that mucosa‐associated lymphoid tissue (MALT) lymphoma, ALCL, and mycosis fungoides (MF) can be successfully treated to complete remission with a low‐dose radiation that can vary from 4 Gy (MALT), 6 Gy (ALCL), and 12 Gy (MF) . Brachytherapy with a dose of 8 Gy has also been shown to be highly efficacious in treating facial MF …”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that intermediate‐dose (> 20 Gy) to high‐dose (> 50 Gy) radiotherapy in pediatric patients can increase secondary cancer risk, such as basal cell carcinoma, since children have enhanced radiosensitivity and expected longevity . However, low‐dose radiation has relatively low risk of both acute and long‐term toxicities and can still provide a complete remission even when aggressive markers are shown on pathology . Based on recent studies and our clinical experience of past successful treatments of primary skin lymphomas in children, we decided 4 Gy in two fractions would be sufficient and safe, even with the high Ki67 of his lesion.…”

Section: Discussionmentioning

confidence: 99%

Primary cutaneous CD4+ small‐ to medium‐sized pleomorphic T‐cell lymphoproliferative disorder in a pediatric patient successfully treated with low‐dose radiation

Kim

Aria

Wilmas

et al. 2018

Pediatric Dermatology

View full text Add to dashboard Cite

Primary cutaneous CD4+ small‐ to medium‐sized pleomorphic T‐cell lymphoproliferative disorder (PCSM‐LPD) is a rare and low‐grade form of cutaneous T‐cell proliferation with the average age of diagnosis of 54 years. Because of its rarity, the etiology or exact clinicopathology of PCSM‐LPD remains unclear, with < 10 pediatric cases reported. A 13‐year‐old boy presented to our clinic with a raised tumor with PCSM‐LPD histology and was successfully treated with ultra‐low‐dose radiation therapy. While no standard of care has been established for pediatric PCSM‐LPD, this report represents an example of achieving remission in a pediatric tumor with minimal potential for therapy‐related long‐term toxicity.

show abstract

Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients

Cited by 24 publications

References 28 publications

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

Management Trends and Outcomes for Stage I to II Mantle Cell Lymphoma Using the National Cancer Data Base: Ascertaining the Ideal Treatment Paradigm

Primary cutaneous CD4+ small‐ to medium‐sized pleomorphic T‐cell lymphoproliferative disorder in a pediatric patient successfully treated with low‐dose radiation

Contact Info

Product

Resources

About